Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 761.88 USD -0.52%
Market Cap: 722.1B USD

ROCE
Return on Capital Employed

37.7%
Current
29%
Average
2.6%
Industry

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
37.7%
=
EBIT
19.7B
/
Capital Employed
52.3B

ROCE Across Competitors

Country Company Market Cap ROCE
US
Eli Lilly and Co
NYSE:LLY
724.6B USD
38%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
2%
US
Johnson & Johnson
NYSE:JNJ
368.8B USD
18%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
70%
CH
Roche Holding AG
SIX:ROG
213.5B CHF
29%
CH
Novartis AG
SIX:NOVN
189.6B CHF
26%
UK
AstraZeneca PLC
LSE:AZN
166B GBP
18%
US
Merck & Co Inc
NYSE:MRK
196.7B USD
25%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
5%
US
Pfizer Inc
NYSE:PFE
132.6B USD
10%
FR
Sanofi SA
PAR:SAN
109.5B EUR
20%

Eli Lilly and Co
Glance View

Economic Moat
Wide
Market Cap
722.1B USD
Industry
Pharmaceuticals

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
359.52 USD
Overvaluation 53%
Intrinsic Value
Price
What is Return on Capital Employed?

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
37.7%
=
EBIT
19.7B
/
Capital Employed
52.3B
What is the ROCE of Eli Lilly and Co?

Based on Eli Lilly and Co's most recent financial statements, the company has ROCE of 37.7%.

Back to Top